EUVIMEDEUVIMED entdecken
Crossref

Targeting Lung Cancer: Synthesis, Characterization, Enzyme Inhibition, and Antiproliferative Activity of 1 H ‐Benzo[ f ]chromen‐1‐One‐Thiosemicarbazones Supported by Molecular Docking

Shahid Raza, Muhammad Islam iD, Furkan Çakır iD, Şeyma Ateşoğlu, Fahri Akbaş, Parham Taslimi iD, İlhami Gülçin iD, Salman F Alamery, Abdallah M Elgorban, Faiqa Noreen, Mazhar Hussain, Zahid Shafiq iD und 1 weitere

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70116 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Shahid Raza und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemical Sciences, Bahauddin Zakariya University, Multan, Pakistan. Hauptthemen laut MEDLINE: Antineoplastic Agents, Lung Neoplasms, Carbonic Anhydrase Inhibitors, Thiosemicarbazones. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: The authors extend their appreciation to the Ongoing Research Funding Program (ORF-2025-241), King Saud University, Riyadh, Saudi Arabia..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this study is to design, synthesize, and characterize novel benzo [f] chromene‐substituted thiosemicarbazone derivatives as potential anticancer agents, based on the rationale of simultaneously targeting key cancer‐related enzymes and signaling pathways to improve therapeutic efficacy against lung cancer. For these purposes, 18 novel thiosemicarbazone derivatives 4a–r were synthesized. Among them, compound 4p exhibited the most promising anticancer effects against A549 cells, with an IC 50 value of 5.11 µM and a selectivity index (SI) of 10.55, surpassing the reference drug sorafenib. Compound 4p also demonstrated potent enzyme inhibitory activity, particularly against hCA I (IC 50 = 104.26 nM) and hCA II (IC 50 = 95.18 nM), outperforming acetazolamide. In anticancer assays, compound 4p (SI = 10.55) was about twice as effective as sorafenib (SI = 5.34), and in enzyme inhibition, it showed ~1.5‐fold greater potency than acetazolamide. Molecular docking studies show strong binding interactions of 4p with hCA I, hCA II, and BRAF, with favorable docking scores and stable protein–ligand complexes confirmed by 100‐ns and 250‐ns triplicate random seed MD simulations. Additionally, pharmacokinetic predictions indicated excellent drug‐like properties for 4p , including high permeability, oral absorption, and adherence to Lipinski's rule. These findings highlight compound 4p as a promising candidate for an anticancer agent targeting key enzymes involved in lung cancer progression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsLung NeoplasmsCarbonic Anhydrase InhibitorsThiosemicarbazonesBenzopyransHumansMolecular Docking SimulationStructure-Activity RelationshipCell ProliferationMolecular StructureDrug Screening Assays, AntitumorA549 CellsDose-Response Relationship, Drug

Stichwörter der Autor:innen

benzo[f]chromenecarbonic anhydraselung cancermolecular dockingmolecular dynamics

Substanzen

Antineoplastic AgentsCarbonic Anhydrase InhibitorsThiosemicarbazonesBenzopyrans

Autor:innen und Institutionen

  • Institute of Chemical Sciences, Bahauddin Zakariya University, Multan, Pakistan.
  • School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Bezmialem Vakif University, Istanbul, Türkiye.
  • Department of Medical Biology, Faculty of Medicine, Bezmialem Vakif University, Istanbul, Türkiye.
  • Department of Biotechnology, Institute of Health Sciences, Bezmialem Vakif University, Istanbul, Türkiye.
  • Department of Biotechnology, Faculty of Science, Bartin University, Bartin, Türkiye.

ORCID-Profile: Muhammad Islam, Furkan Çakır, Parham Taslimi, İlhami Gülçin, Zahid Shafiq, Halil Şenol

Förderung

  • The authors extend their appreciation to the Ongoing Research Funding Program (ORF-2025-241), King Saud University, Riyadh, Saudi Arabia.

Zitieren

APA

Raza, S., Islam, M., Çakır, F., Ateşoğlu, Ş., Akbaş, F., Taslimi, P., Gülçin, İ., Alamery, S. F., Elgorban, A. M., Noreen, F., Hussain, M., Shafiq, Z., & Şenol, H. (2025). Targeting Lung Cancer: Synthesis, Characterization, Enzyme Inhibition, and Antiproliferative Activity of 1 H ‐Benzo[ f ]chromen‐1‐One‐Thiosemicarbazones Supported by Molecular Docking. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70116

Vancouver

Raza S, Islam M, Çakır F, Ateşoğlu Ş, Akbaş F, Taslimi P, et al. Targeting Lung Cancer: Synthesis, Characterization, Enzyme Inhibition, and Antiproliferative Activity of 1 H ‐Benzo[ f ]chromen‐1‐One‐Thiosemicarbazones Supported by Molecular Docking. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70116

BibTeX
@article{Raza2025,
  author = {Raza, Shahid and Islam, Muhammad and Çakır, Furkan and Ateşoğlu, Şeyma and Akbaş, Fahri and Taslimi, Parham and Gülçin, İlhami and Alamery, Salman F and Elgorban, Abdallah M and Noreen, Faiqa and Hussain, Mazhar and Shafiq, Zahid and Şenol, Halil},
  title = {Targeting Lung Cancer: Synthesis, Characterization, Enzyme Inhibition, and Antiproliferative Activity of 1 H ‐Benzo[ f ]chromen‐1‐One‐Thiosemicarbazones Supported by Molecular Docking},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70116}
}
Kostenlos starten →